Crossmark

Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial

Crossref DOI link: https://doi.org/10.1186/s12879-018-3493-y

Published Online: 2018-11-15

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Reischig, Tomas https://orcid.org/0000-0002-5404-598X
Kacer, Martin

Hruba, Petra

Hermanova, Hana

Hes, Ondrej

Lysak, Daniel

Kormunda, Stanislav

Bouda, Mirko
Funding

Funding for this research was provided by:

Ministry of Education, Youth and Sports of the Czech Republic (National Sustainability Program I [LO1503])

Charles University, Prague, Czech Republic (Progres Q39)

Institute for Clinical and Experimental Medicine, Prague, Czech Republic (MZO 00023001)
License Information

Text and Data Mining valid from 2018-11-15
More Information

Article History

Received: 6 March 2018

Accepted: 1 November 2018

First Online: 15 November 2018

Ethics approval and consent to participate

: The study was approved by the Charles University Teaching Hospital Ethics Committee and conducted in compliance with the Declaration of Helsinki and Declaration of Istanbul. Written informed consent was obtained before enrollment. Trial registration: Australian New Zealand Clinical Trials Registry (ACTRN12610000016033)

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below